Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MYGN vs GENZ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

MYGN Overall Winner 6-Pillar Tally: MYGN 6 – 0 GENZ Matrix Metrics: MYGN 9 – 1 GENZ

As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over GENZ (GENZ) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin), whereas GENZ carries 44.3/100 (HOLD) at $36.39 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1); meanwhile GENZ is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYGN vs GENZ
MYGN NASDAQ Head-to-Head Winner
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.68β · 122% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 30.0 Fund 43.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $5.94 · SMA50: $4.80
GENZ US Equity
GENZ
Institutional Equity
$36.39
-2.5% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.85β · 27% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 49.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 43
RSI-14: 42.5 · SMA20: $37.28 · SMA50: $37.48

6-Pillar Scorecard Institutional Category Breakdown (MYGN 6 – 0 GENZ)

Columns: Metric · MYGN · GENZ
1. Valuation Multiples MYGN
Forward P/E 54.0x N/M
Trailing P/E 54.0x N/M
PEG Ratio 1.40x N/M
EV / Revenue 0.8x N/M
2. Growth & Scale MYGN
Revenue Growth (YoY) -1.5% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $804M N/A
Market Cap $542.9M N/A
3. Profitability & Quality MYGN
Gross Margin 68.3% N/A
Operating Margin -13.3% N/A
Net Profit Margin -16.1% N/A
Return on Equity (ROE) -40.2% N/A
4. Balance Sheet & Cash Flow MYGN
Cash Generation (TTM) -$38M N/A
Cash Flow Margin -4.7% N/A
Net Cash / Leverage $102M Net Debt (0.78x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYGN
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 124.6% (22nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity 81.6% of Rev ($656M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYGN (9) vs GENZ (1)
Institutional Metric MYGN GENZ Criterion Row Edge
Market Capitalization
Scale
$542.9M N/A Larger Scale MYGN
Trailing P/E Ratio
Valuation
54.0x N/M Lower Multiple MYGN
Forward P/E Ratio
Valuation
54.0x N/M Lower Multiple MYGN
Revenue Growth (YoY)
Growth
-1.5% N/A Higher Growth MYGN
Operating Margin (TTM)
Profitability
-13.3% N/A Higher Margin MYGN
Net Profit Margin
Profitability
-16.1% N/A Higher Margin MYGN
Return on Equity (ROE)
Capital Efficiency
-40.2% N/A Higher ROE MYGN
52-Week Range Position
Momentum
53% ($3–$8) 32% ($34–$41) Stronger Trend MYGN
Beta / 30D Volatility
Risk Regime
0.68β · 122% Vol 0.85β · 27% Vol Lower Realized Risk GENZ
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite MYGN
Trailing 12M Revenue (USD)
Operating Scale
$804M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.40x PEG · 0.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$38M ($102M Net Debt (0.78x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +43.93 pp
MYGN: +39.95% · GENZ: -3.98%
3M Horizon MYGN +101.08 pp
MYGN: +94.08% · GENZ: -7.0%
6M Horizon MYGN +50.12 pp
MYGN: +52.6% · GENZ: +2.48%
1Y Horizon MYGN +21.43 pp
MYGN: +25.45% · GENZ: +4.02%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYGN vs GENZ. Trailing 12-month operating profitability (MYGN -13.3% vs GENZ N/A) and valuation multiples (MYGN 54.0x vs GENZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MYGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$804M
Gross Margin68.3%
Op. Margin-13.3%
ROE / Fwd P/E-40.2% · 54.0x
GENZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GENZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GENZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $542.9M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published
GENZ Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYGN vs GENZ Key Questions & Quantitative Answers

As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over GENZ (GENZ) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin), whereas GENZ carries 44.3/100 (HOLD) at $36.39 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1); meanwhile GENZ is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYGN leads the Growth & Scale pillar: MYGN posts -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin), compared with GENZ at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MYGN generates $804M in USD-normalized revenue versus N/A for GENZ. In operating R&D and SG&A reinvestment, MYGN deploys 81.6% of Rev ($656M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GENZ.

MYGN screens cheaper on headline valuation multiples. MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin), whereas GENZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYGN (-40.2% ROE) versus GENZ (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.68β · 122% Vol realized risk). By comparison, GENZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.